PDCD1 and neoplasm: In comparison, there is a modest increase in IL-12 production, and a substantial increase in IFNγ, CD4+ Th1 cells, and cytotoxic CD8+ T-cell levels, which makes the tumor micro-environment more favorable for responding to anti-PD-1 immunotherapy.